Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia

Atherosclerosis

Volumn 210, Issue 1, 2010, Pages 202-208

  Ose, Leiv ^a   Budinski, Dragos ^b   Hounslow, Neil ^b   Arneson, Valerie ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Kowa Research Europe Ltd   (United Kingdom)

^c PharmaNet Ltd   (United Kingdom)

Author keywords

Cardiovascular disease treatment; Combined dyslipidemia; Dyslipidemia treatment; High density lipoprotein cholesterol; Hydroxymethylglutaryl CoA Reductase inhibitors; Low density lipoprotein cholesterol; Pitavastatin; Primary hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; VITAL SIGN;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG TOLERANCE; DYSLIPIDEMIAS; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; MALE; MIDDLE AGED; QUINOLINES;

EID: 77952420085     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.12.009     Document Type: Article

References (24)

1. Cardiovascular diseases, <>; 2009. http://www.who.int/cardiovascular_diseases/en/.
2. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1268. Cholesterol Treatment Trialists' (CTT) Collaborators.
3. Joint Formulary Committee. British National Formulary. 57th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, ; 2009 [accessed 30 06 09]. http://www.bnf.org.uk/bnf/bnf/current/33422.htm.
4. Graham D.J., Staffa J.A., Shatin D., et al. Incidence of hospitalised rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004, 292:2585-2590.
5. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988, 9:571-600. European Atherosclerosis Society.
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. Expert panel on Detection, Evaluation, And Treatment Of High Blood Cholesterol In Adults.
7. Foley K.A., Simpson R.J., Crouse J.R., et al. Effectiveness of statin titration on low density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003, 92:79-81.
8. Phatak H., Wentworth C., Sazonov V., et al. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis 2009, 202:225-233.
9. Aoki T., Nishimura H., Nakagawa S., et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 1997, 47:904-909.
10. Morikawa S., Umetani M., Nakagawa S., et al. Relative induction of mRNA for HMG-CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000, 7:138-144.
11. Stender S., Robust H.N. Efficacy of pitavastatin and comparable safety to pravastatin. Atherosclerosis Suppl 2009, 10(2):2770. abstract.
12. Yokote K., Bujo H., Hanaoka H., et al. Multicenter collaborative randomised parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008, 201:345-352.
13. Budinski D., Arneson V., Hounslow N., et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009, 4(3):291-302.
14. Budinski D., Arneson V., Hounslow N., et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009, 25(11):2755-2764.
15. Aviram M. Interaction of oxidised low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur J Clin Chem Clin Biochem 1996, 34:599-608.
16. Hamilton C.A. Low density lipoprotein and oxidised low density lipoprotein: their role in the development of atherosclerosis. Pharmacol Ther 1997, 74:55-72.
17. Sviridov D., Nestel P., Watts G. Statins and metabolism of high density lipoprotein. Cardiovasc Hematol Agents Med Chem 2007, 5:215-221.
18. Cziraky M.J., Willey V.J., McKenney J.M., et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006, 97:61C-68C.
19. Beaird S.L. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc 2000, 40:637-644.
20. Hayashi T., Yokote K., Saito Y., et al. Pitavastatin: efficacy and safety in intensive lipid-lowering. Expert Opin Pharmacother 2007, 8:2315-2327.
21. Ando H., Tsuruoka S., Yanagihara H., et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 2005, 60:494-497.
22. Nakagawa S., Hounslow N. Pitavastatin is not subject to clinically relevant pharmacokinetic interactions when administered with CYP3A4 inhibitors in healthy volunteers. Eur Heart J 2009, 30(Abstract suppl.):958.
23. Lipitor Summary of Product Characteristics >; 2009. http://emc.medicines.org.uk/medicine/1424/SPC/Lipitor+10mg%2c+20mg%2c+40mg%2c+80mg+Tablets/.
24. Kurihara Y., Douzono T., Kawakita K., et al. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO Tablet). Jpn Pharmacol Ther 2008, 36:709-731.